PEB's Principal Activity is the development and deployment of specialist cancer diagnostics tools.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-|
|vs ASX 200 (1yr)||-54.42%|
Pacific Edge Limited (PEB) is a cancer diagnostics company. It is being in to discovering, building and commercialising innovative cancer diagnostic tests that can contribute to a clinically meaningful difference in the detection and management of cancer.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Mr Tony Barclay||Non-Executive Director||Mar 2022||
Mr Tony Barclay
Mr Barclay is an experienced healthcare industry executive and has experience in corporate finance and healthcare technology companies. He was formerly Chief Financial Officer and Company Secretary of Fisher & Paykel Healthcare (FPH) from when the healthcare business was separated from Fisher & Paykel Appliances in 2001. From then he led the finance team and was a member of the senior leadership team until 2018. He is currently Independent Chair of Izon Science, a Christchurch-based manufacturer of nano-biological separation and characterisation tools and Chair of Australian-based Baymatob, a company involved in women's health and AI-guided monitoring for pregnancy and labour. He is also an Independent Director of Veriphi, an Auckland-based technology company developing intravenous drug identity and concentration verification devices.
|Dr Peter Meintjes||Chief Executive Officer||Jan 2022|
|Mr Anatole Masfen||Non-Executive Director||N/A||
Mr Anatole Masfen
Mr Masfen is the co-founder of Artemis Capital, a private equity investment firm based in Auckland. He has spent eight years with Air New Zealand (and later the merged entity with Ansett Australia) holding senior positions in Pricing, Revenue Management and Systems implementation. He holds directorships in numerous private companies and has knowledge of financial capital markets. He also has a detailed knowledge of the medical sector and future trends. In particular human sciences and disruptive technologies. He is also a Chair of Capital Committee and member of Risk committee.
|Dr Bryan Raymond George Williams||Non-Executive Director||N/A||
Dr Bryan Raymond George Williams
Dr Williams is an internationally recognised cancer researcher and research administrator, with business experience. He has held a number of governance roles, including with a NASDAQ listed biotech company. Presently, he serves on the Board of two privately held Australian biotechnology companies. He was Director and CEO of the Hudson Institute of Medical Research. He is currently Emeritus Director and Distinguished Scientist at the Hudson Institute in Melbourne.
|Mr Christopher (Chris) John Gallaher||Non-Executive Chairman,Non-Executive Director||N/A||
Mr Christopher (Chris) John Gallaher
Non-Executive Chairman,Non-Executive Director
Mr Gallaher has held senior positions in both CEO and CFO roles with a number of international companies and was a partner in Arthur Young, Chartered Accountants. Prior to retiring from full time corporate life, he was CFO of Fulton Hogan, a NZ resources based civil contractor. He is also Chairman of Mariposa Holdings, a charitable organisation. He is also a member of Risk & Capital committee.
|Ms Sarah Natalie Park||Non-Executive Director||N/A||
Ms Sarah Natalie Park
Ms Park has international corporate finance experience with PricewaterhouseCoopers in New Zealand and HSBC Investment Bank in London. During her executive career, she worked in M&A, equity capital markets and was previously an Equity Research Analyst. She also had a lead role in seeking private capital from Asia, the Middle East and Europe for early-stage US biopharmaceutical companies. Ms Park is a Director of National Provident Fund and Hawke's Bay Airport. She has a focus on providing her Audit & Risk capability and experience to her directorship portfolio. She is also chair of Risk Committee and a member of Capital Committee.
|Ms Anna Kate Stove||Non-Executive Director||N/A||
Ms Anna Kate Stove
Ms Stove has a 25+ year track record in leading and driving transformational change within the pharmaceutical sector. She has Global business experience having held a variety of senior executive roles within NZ, Asia Pacific and Europe. She recently retired from being NZ General Manager at GlaxoSmthKline & she is now committed to growing businesses through best practice governance. She is currently the Chair of Global Women, Director of TAB NZ & Director of Rua Bioscience.
|Mr Mark Green||Non-Executive Director||N/A||
Mr Mark Green
Mr Green is an experienced corporate finance professional, with 25 years of experience in the Australasian capital, corporate and financial markets. He was an Executive Director for Investment Banking at Goldman Sachs where he worked for nearly 20 years and has been involved in many New Zealand transactions including the IPOs of Meridian, Mighty River Power and Vector. He is a Director of a number of entities including being Chair of Astrolab VC Investment Committee and a Director of Mariposa Holdings (a charitable organisation).
|Mr Grant Edward Gibson||Chief Financial Officer,Company Secretary||N/A|
|Peter Meintjes||Chief Executive Officer||N/A|
PEB directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|21/04/22||David Darling||Issued||92,985||$1.00||$92,985||Issue of securities|
|20/10/21||David Darling||Issued||37,037||$1.35||$50,000||Rights issue|
|05/10/21||David Darling||Sell||+139,478||$1.426||($198,838)||On-market trade|
The current holdings of PEB directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Christopher (Chris) Gallaher||N/A||N/A||N/A||N/A||N/A|
No Substantial Shareholders for PEB in our database.
12 month transaction history compiled from ASX announcements.
No buy transactions reported by Substantial Shareholders in the past 12 months.
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.